UBS analyst Danielle Antalffy downgraded Inspire Medical (INSP) to Neutral from Buy with a price target of $89, down from $230. The firm cites elevated downside risks to near term-sales growth and EPS estimates for the downgrade. Recent physician checks suggest that the headwinds highlighted during the Q2 earnings call will likely require time and higher OpEx to resolve, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP: